What is disappointing is that Abbott took a very aggressive approach with this drug, ... They clearly made a poor decision.

We hope to learn more about the status of the FDA letter on Tuesday.

We continue to forecast solid low-to-mid-teens sales growth and high-teens earnings per share growth throughout fiscal 2001 despite the crippling effects of the (weak) euro,

Overall, we believe that the earnings outlook for Medtronic is the strongest in the industry, and Medtronic remains the one company that we have the most confidence in with respect to delivering on its earnings guidance,

Today's weakness in the stock is reflective of investors expecting more compelling and cleaner data from both trials,

We're not a million miles away, but some of our decision making has been poor and we've got to rectify that. Under pressure, we've tended to do the wrong thing, and that has resulted in the concession of a few fairly soft tries.